Additional laboratory based studies are presently defining PTEN functionality in all patients from this trial, and whether reduced PTEN function and tumor cell sensitivity in any of these patients correlated with higher basal activities of AKT, mTOR, p70 S6K, and ERK1/2 as was observed in our pre-clinical studies. This evidence concerns the gene AKT1 and neoplasm.